WATAG Advisory Note

WATAG Advisory Note guidelines FOR THE PHARMACOLOGICAL treatment OF NEUROPATHIC PAIN (2017). Purpose The purpose of this Advisory Note is to provide WA public health services with a 2017. version of guidelines for the treatment of neuropathic pain. Scope Neuropathic pain is defined as pain caused by a disease or lesion of the somatosensory nervous system. The disease or lesion can be located in the peripheral ( diabetic neuropathy) or central nervous system ( after spinal cord injury or stroke). The treatment options presented in these guidelines are for different conditions within the spectrum of neuropathic pain. It is recommended that therapeutic agents should be selected and trialed according to the recommendations provided in these guidelines . Background Neuropathic pain is often refractory or inadequately managed by common analgesics;. in particular paracetamol and NSAIDs are usually ineffective. Therefore the guidelines provided here should guide choice of therapeutic agents.

WATAG| Advisory Note: Neuropathic Pain Guidelines 2017 5 Acute neuropathic pain conditions requiring parenteral treatment (Acute SCI, acute plexus injury, Guillain-Barré Syndrome, severe CRPS)

Loading..

Tags:

  Notes, Guidelines, Treatment, Acute, Advisory, Watag advisory note, Watag

Information

Related search queries